Indication intelligence, analysis and sector perception

Neuralstem (CUR) the next TOEs up

June 13, 2016 9:21am

Additional reorganization – too LITTLE, much too late “moves”

Neuralstem has now disclosed voluntary salary reductions of senior management as well as a reduction in non-employee board member compensation from $200,000 per annum to $100,000 per annum, payable in options, restricted stock or restricted stock units.

CUR furthers its reorganization plans and focus on clinical development, that Richard Daly, CUR’s president and CEO, has been appointed chairman of the board of directors. Mr. Daly’s appointment as chairman will allow Dr. Karl Johe, CUR’s founder, CSO and former chairman, to focus exclusively on the development of product candidates.

The Bottom Line: The “writings” have been on the wall for years …

CUR closed at $0.33, DOWN -$0.04 – RUN don’t walk.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 47 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.